In 12 months, the Cancer Moonshot has made great strides, secured $1.8 billion in funding and seeded countless projects, partnerships, and possibilities. One year on, a new administration has the power to undo it all.
Gritstone Oncology launched in late 2015, with a $102 million Series A that hinted at some lofty goals for cancer immunotherapy. Some 18-months later, it's presenting the first of its data at the American Association for Cancer Research (AACR) annual meeting.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.